The Endocannabinoid System: A Plain-Language Guide for Patients and Clinicians

What Is the Endocannabinoid System?

The endocannabinoid system (ECS) is a lipid-based retrograde neurotransmitter system that regulates a remarkable range of physiological processes — pain, mood, appetite, memory, sleep, immune function, and more. It was discovered in the early 1990s by researchers studying how THC (the primary psychoactive compound in cannabis) produces its effects in the brain. What they found was unexpected: the human body had its own system of receptors perfectly shaped to receive cannabinoid molecules — and it produced its own cannabinoid-like chemicals to activate them.

The ECS has three core components: (1) endocannabinoids — the body's own cannabis-like molecules; (2) receptors — proteins on cell surfaces that endocannabinoids bind to; and (3) metabolic enzymes — proteins that synthesize and break down endocannabinoids. Understanding each component is key to understanding how cannabis medicines work.

The Two Main Receptors: CB1 and CB2

CB1 receptors are among the most abundant G protein-coupled receptors (GPCRs) in the brain. They are concentrated in regions that explain many of cannabis's effects: the hippocampus (memory), prefrontal cortex (decision-making, anxiety), amygdala (fear, emotion), basal ganglia (movement, reward), cerebellum (coordination), and periaqueductal gray (pain modulation). When THC binds to CB1 receptors, it mimics the action of endocannabinoids — but with greater potency and duration, producing the characteristic psychoactive effects.

CB2 receptors are primarily expressed on immune cells — B cells, NK cells, monocytes, macrophages — and in peripheral tissues including the spleen, liver, and gut. They are less abundant in the brain under normal conditions, but their expression increases dramatically during neuroinflammation. CB2 activation generally produces anti-inflammatory effects without psychoactivity, making CB2-selective agonists attractive therapeutic targets for inflammatory and autoimmune conditions.

Endocannabinoids: The Body's Own Cannabis

The two primary endocannabinoids are anandamide (AEA, N-arachidonoylethanolamine) and 2-arachidonoylglycerol (2-AG). Anandamide was the first endocannabinoid identified, in 1992, by Raphael Mechoulam's group. Its name comes from the Sanskrit word "ananda" meaning bliss — reflecting its role in mood regulation. Anandamide is a partial agonist at CB1 and CB2 receptors and also activates TRPV1 channels (the "capsaicin receptor"), contributing to pain modulation.

2-AG is the most abundant endocannabinoid in the brain — present at concentrations 170-fold higher than anandamide. It is a full agonist at both CB1 and CB2 receptors and is the primary endogenous ligand for CB2. Unlike classical neurotransmitters, endocannabinoids are synthesized on demand from membrane phospholipids and act as retrograde messengers — released from postsynaptic neurons to modulate presynaptic neurotransmitter release. This retrograde signaling mechanism allows neurons to regulate their own incoming signals, making the ECS a master regulator of synaptic tone.

Metabolic Enzymes: FAAH and MAGL

Endocannabinoids are rapidly degraded after synthesis. Anandamide is primarily broken down by fatty acid amide hydrolase (FAAH), while 2-AG is degraded mainly by monoacylglycerol lipase (MAGL). These enzymes are important therapeutic targets: FAAH inhibitors raise anandamide levels without directly activating cannabinoid receptors, potentially offering anxiolytic and analgesic effects with a more favorable side-effect profile than direct CB1 agonists. Several FAAH inhibitors are in clinical development for anxiety and pain.

Why the ECS Matters for Cannabis Medicine

Phytocannabinoids (plant-derived cannabinoids) work primarily by interacting with the ECS. THC is a partial agonist at CB1 and CB2 receptors — it mimics endocannabinoids but with greater potency and longer duration. CBD does not directly bind CB1 or CB2 with high affinity; instead, it modulates the ECS indirectly by inhibiting FAAH (raising anandamide), acting as a negative allosteric modulator of CB1 (reducing THC's psychoactive effects), and activating non-ECS targets including 5-HT1A receptors and TRPV1 channels.

The ECS is implicated in virtually every major disease category — pain, neurodegeneration, cancer, metabolic disorders, immune dysregulation, and psychiatric conditions. This breadth explains both the therapeutic potential of cannabinoids and the complexity of their effects. Targeting the ECS is not like targeting a single receptor for a single disease — it is modulating a system that touches nearly every aspect of human physiology.

The Endocannabinoid Deficiency Hypothesis

In 2004, neurologist Ethan Russo proposed the "clinical endocannabinoid deficiency" (CED) hypothesis — the idea that some conditions (migraine, fibromyalgia, irritable bowel syndrome) may result from insufficient endocannabinoid tone. While the hypothesis remains controversial and lacks direct clinical evidence, it provides a theoretical framework for why cannabis may benefit conditions that conventional medicine struggles to treat. Research into ECS biomarkers (anandamide levels, CB1 receptor density) in these conditions is ongoing.